Premium
The Alzheimer's Disease Neuroimaging Initiative: Progress report and future plans
Author(s) -
Weiner Michael W.,
Aisen Paul S.,
Jack Clifford R.,
Jagust William J.,
Trojanowski John Q.,
Shaw Leslie,
Saykin Andrew J.,
Morris John C.,
Cairns Nigel,
Beckett Laurel A.,
Toga Arthur,
Green Robert,
Walter Sarah,
Soares Holly,
Snyder Peter,
Siemers Eric,
Potter William,
Cole Patricia E.,
Schmidt Mark
Publication year - 2010
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2010.03.007
Subject(s) - alzheimer's disease neuroimaging initiative , neuroimaging , atrophy , pittsburgh compound b , cognition , medicine , clinical trial , cognitive decline , cerebrospinal fluid , disease , cognitive impairment , alzheimer's disease , psychology , brain structure and function , neuroscience , oncology , dementia
The Alzheimer's Disease Neuroimaging Initiative (ADNI) beginning in October 2004, is a 6‐year research project that studies changes of cognition, function, brain structure and function, and biomarkers in elderly controls, subjects with mild cognitive impairment, and subjects with Alzheimer's disease (AD). A major goal is to determine and validate MRI, PET images, and cerebrospinal fluid (CSF)/blood biomarkers as predictors and outcomes for use in clinical trials of AD treatments. Structural MRI, FDG PET, C‐11 Pittsburgh compound B (PIB) PET, CSF measurements of amyloid β (Aβ) and species of tau, with clinical/cognitive measurements were performed on elderly controls, subjects with mild cognitive impairment, and subjects with AD. Structural MRI shows high rates of brain atrophy, and has high statistical power for determining treatment effects. FDG PET, C‐11 Pittsburgh compound B PET, and CSF measurements of Aβ and tau were significant predictors of cognitive decline and brain atrophy. All data are available at UCLA/LONI/ADNI, without embargo. ADNI‐like projects started in Australia, Europe, Japan, and Korea. ADNI provides significant new information concerning the progression of AD.